FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322743737> ?p ?o ?g. }

• W4322743737 endingPage "1529" @default.
• W4322743737 startingPage "1529" @default.
• W4322743737 abstract "Background: The 21-gene Oncotype DX Breast Recurrence Score® assay is prognostic and predictive of chemotherapy benefit for patients with estrogen receptor-positive, HER2− early breast cancer (EBC). The KARMA Dx study evaluated the impact of the Recurrence Score® results (RS) on the treatment decision for patients with EBC and high-risk clinicopathological characteristics for whom chemotherapy (CT) was considered. Methods: Eligible patients with EBC were candidates for the study if CT was considered standard recommendation by local guidelines. Three high-risk EBC cohorts were predefined: (A) pT1-2, pN0/N1mi, and grade 3; (B) pT1-2, pN1, and grades 1–2; and (C) neoadjuvant cT2-3, cN0, and Ki67 ≤ 30%. Treatment recommendations before and after 21-gene testing were registered, as well as treatment received and physicians’ confidence levels in their final recommendations. Results: A total of 219 consecutive patients were included from eight Spanish centers: 30 in cohort A, 158 in cohort B, and 31 in cohort C. Ten patients were excluded from the final analysis as CT was not initially recommended. After 21-gene testing, treatment decisions changed from CT + endocrine therapy (ET) to ET alone for 67% of the whole group. In total, 30% (95% confidence interval [CI] 15% to 49%), 73% (95% CI 65% to 80%), and 76% (95% CI 56% to 90%) of patients ultimately received ET alone in cohorts A, B, and C, respectively. Physicians’ confidence in their final recommendations increased in 34% of cases. Conclusions: Use of the 21-gene test resulted in an overall 67% reduction in CT recommendation in patients considered candidates for CT. Our findings indicate the substantial potential of the 21-gene test to guide CT recommendations in patients with EBC considered to be at high risk of recurrence based on clinicopathological parameters, regardless of nodal status or treatment setting." @default.
• W4322743737 created "2023-03-03" @default.
• W4322743737 creator A5010399021 @default.
• W4322743737 creator A5010660745 @default.
• W4322743737 creator A5035102028 @default.
• W4322743737 creator A5045301167 @default.
• W4322743737 creator A5053722517 @default.
• W4322743737 creator A5061562225 @default.
• W4322743737 creator A5066805730 @default.
• W4322743737 creator A5075755020 @default.
• W4322743737 creator A5077463490 @default.
• W4322743737 creator A5079406849 @default.
• W4322743737 creator A5080951622 @default.
• W4322743737 creator A5084883054 @default.
• W4322743737 date "2023-02-28" @default.
• W4322743737 modified "2023-10-18" @default.
• W4322743737 title "Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study" @default.
• W4322743737 cites W1923080481 @default.
• W4322743737 cites W2096997068 @default.
• W4322743737 cites W2105882193 @default.
• W4322743737 cites W2113344831 @default.
• W4322743737 cites W2115162082 @default.
• W4322743737 cites W2130639106 @default.
• W4322743737 cites W2145747877 @default.
• W4322743737 cites W2160377567 @default.
• W4322743737 cites W2190954851 @default.
• W4322743737 cites W2289933199 @default.
• W4322743737 cites W2502134830 @default.
• W4322743737 cites W2512615678 @default.
• W4322743737 cites W2592904882 @default.
• W4322743737 cites W2598843906 @default.
• W4322743737 cites W2603868227 @default.
• W4322743737 cites W2605509116 @default.
• W4322743737 cites W2728077452 @default.
• W4322743737 cites W2753134540 @default.
• W4322743737 cites W2805734855 @default.
• W4322743737 cites W2891728587 @default.
• W4322743737 cites W2900493371 @default.
• W4322743737 cites W2907204290 @default.
• W4322743737 cites W2947463548 @default.
• W4322743737 cites W2947509154 @default.
• W4322743737 cites W2948923376 @default.
• W4322743737 cites W2962821411 @default.
• W4322743737 cites W2965857754 @default.
• W4322743737 cites W2967584098 @default.
• W4322743737 cites W2977150399 @default.
• W4322743737 cites W3120924451 @default.
• W4322743737 cites W3157389007 @default.
• W4322743737 cites W4226218519 @default.
• W4322743737 doi "https://doi.org/10.3390/cancers15051529" @default.
• W4322743737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36900321" @default.
• W4322743737 hasPublicationYear "2023" @default.
• W4322743737 type Work @default.
• W4322743737 citedByCount "0" @default.
• W4322743737 crossrefType "journal-article" @default.
• W4322743737 hasAuthorship W4322743737A5010399021 @default.
• W4322743737 hasAuthorship W4322743737A5010660745 @default.
• W4322743737 hasAuthorship W4322743737A5035102028 @default.
• W4322743737 hasAuthorship W4322743737A5045301167 @default.
• W4322743737 hasAuthorship W4322743737A5053722517 @default.
• W4322743737 hasAuthorship W4322743737A5061562225 @default.
• W4322743737 hasAuthorship W4322743737A5066805730 @default.
• W4322743737 hasAuthorship W4322743737A5075755020 @default.
• W4322743737 hasAuthorship W4322743737A5077463490 @default.
• W4322743737 hasAuthorship W4322743737A5079406849 @default.
• W4322743737 hasAuthorship W4322743737A5080951622 @default.
• W4322743737 hasAuthorship W4322743737A5084883054 @default.
• W4322743737 hasBestOaLocation W43227437371 @default.
• W4322743737 hasConcept C121608353 @default.
• W4322743737 hasConcept C126322002 @default.
• W4322743737 hasConcept C143998085 @default.
• W4322743737 hasConcept C201903717 @default.
• W4322743737 hasConcept C2776694085 @default.
• W4322743737 hasConcept C29456083 @default.
• W4322743737 hasConcept C44249647 @default.
• W4322743737 hasConcept C530470458 @default.
• W4322743737 hasConcept C71924100 @default.
• W4322743737 hasConcept C72563966 @default.
• W4322743737 hasConcept C84606932 @default.
• W4322743737 hasConceptScore W4322743737C121608353 @default.
• W4322743737 hasConceptScore W4322743737C126322002 @default.
• W4322743737 hasConceptScore W4322743737C143998085 @default.
• W4322743737 hasConceptScore W4322743737C201903717 @default.
• W4322743737 hasConceptScore W4322743737C2776694085 @default.
• W4322743737 hasConceptScore W4322743737C29456083 @default.
• W4322743737 hasConceptScore W4322743737C44249647 @default.
• W4322743737 hasConceptScore W4322743737C530470458 @default.
• W4322743737 hasConceptScore W4322743737C71924100 @default.
• W4322743737 hasConceptScore W4322743737C72563966 @default.
• W4322743737 hasConceptScore W4322743737C84606932 @default.
• W4322743737 hasIssue "5" @default.
• W4322743737 hasLocation W43227437371 @default.
• W4322743737 hasLocation W43227437372 @default.
• W4322743737 hasLocation W43227437373 @default.
• W4322743737 hasOpenAccess W4322743737 @default.
• W4322743737 hasPrimaryLocation W43227437371 @default.
• W4322743737 hasRelatedWork W2348152691 @default.
• W4322743737 hasRelatedWork W2348231456 @default.

• next